论文部分内容阅读
选择80例口服药物控制不佳的2型糖尿病患者,保持原有口服药方案不变,随机分成两组。每组40例,一组加用地特胰岛素1天1次,晚上10:00注射(治疗组);另一组加用甘精胰岛素1天1次,晚上10:00注射(对照组)。治疗期为12周。比较两组治疗前后空腹血糖(FBG)、糖化血红蛋白(HbA1c)、体重变化及低血糖发生情况。结果:两组的HbA1c和FBG同治疗前相比均有明显下降(P<0.01),但组间比较无统计学差异(P>0.05);与对照组相比,治疗组体重增加少,差异有统计学意义(P<0.01)。两组各发生1例低血糖,发生率为2.5%。结论:口服药控制不佳的2型糖尿病患者,加用11天1次地特胰岛素治疗同甘精胰岛素相比,有效性、安全性相似,但体重增加少。
Eighty patients with poorly controlled type 2 diabetes mellitus were selected and their oral dosage regimen unchanged. The patients were randomly divided into two groups. Each group of 40 cases, a group plus detemir treatment once a day, 10:00 at night injection (treatment group); the other group with insulin glargine once a day, 10:00 at night injection (control group). The treatment period is 12 weeks. Fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), body weight changes and hypoglycemia were compared between the two groups before and after treatment. Results: The levels of HbA1c and FBG in both groups decreased significantly (P <0.01), but there was no significant difference between the two groups (P> 0.05). Compared with the control group, the weight gain of the treatment group was less There was statistical significance (P <0.01). One case of hypoglycemia occurred in two groups, the incidence was 2.5%. CONCLUSIONS: Patients with poorly controlled oral administration of type 2 diabetes treated with insulin eleven for eleven days have similar efficacy and safety, but less weight gain, than insulin glargine.